Francisco Kerdel, MD
Dermatology · Miami, FLNPI 1144258724
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,810,628 of the $2,054,148 with a category attached, or 88.1%. It is spread thinly across 49 manufacturers, the largest accounting for just 21.5%. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,572 payments — averaging $798.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$442K
- Lilly USA, LLC$231K
- Amgen$208K
- UCB, Inc.$162K
- Janssen Scientific Affairs, LLC$142K
- Johnson & Johnson$138K
- plus $733K from 43 others
Across 520 payments — averaging $7544.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$913K
- Bausch Health US, LLC$720K
- Janssen Research & Development, LLC$536K
- AbbVie$440K
- Novartis$428K
- Sun Pharmaceutical Industries Inc.$288K
- plus $598K from 14 others
What the payments were for
- Consulting fees$108,2885%
- Speaking & faculty fees$1,810,62888%
- Travel & lodging$65,6283%
- Food & beverage$68,5093%
- Education$1,0960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,054,148 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 79 | $332,012 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $292,351 |
| Skyrizi PenRisankizumab-Rzaa | 13 | $268,831 |
| Dupixent SyringeDupilumab | 66 | $241,619 |
| EnbrelEtanercept | 28 | $226,094 |
| Taltz AutoinjectorIxekizumab | 31 | $200,384 |
| RinvoqUpadacitinib | 25 | $182,989 |
| Humira PenAdalimumab | 12 | $162,083 |
| TremfyaGuselkumab | 11 | $154,408 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $86,720 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 11 | $83,842 |
| OtezlaApremilast | 16 | $83,772 |
| AdbryTralokinumab-Ldrm | 16 | $61,736 |
| SiliqBrodalumab | 11 | $55,835 |
| OpzeluraRuxolitinib Phosphate | 21 | $41,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $207,531 | $309,86644 claims |
| AbbVieRinvoq | $441,747 | $182,98925 claims |
| Johnson & JohnsonTremfya | $137,585 | $154,40811 claims |
| LEO Pharma Inc.Adbry | $72,387 | $61,73616 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $16,536 | $55,83511 claims |
| Incyte CorporationOpzelura | $63,976 | $41,46021 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $756 | $25,82426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,147 dermatology providers in Florida.
Other dermatology in Miami
- Robert KirsnerMiami$1.4M
- Gil YosipovitchMiami$1M
- Mercedes GonzalezMiami$943K
- Heather Woolery LloydMiami$609K
- Hadar Lev-TovMiami$326K
- Lawrence SchachnerMiami$309K
- Giovanna CioccaMiami$222K
- Janice Lima MaribonaMiami$217K
- Jill WaibelMiami$116K
- Ana DuarteMiami$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.